BPH Global Ltd

Nutura Organic Ltd – Term Sheet to commence Pilot Study

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company has entered into a legally binding Term Sheet (Term Sheet) with Australian-based company Nutura Organic Ltd (Nutura) for the purchase of adult milk formula to enable the Company to undertake a pilot study in China.


Highlights

  • Purchase of adult milk formula to commence pilot study in China
  • Proposed development of adult milk formula products infused with TCM ingredients including sialic acid and nutraceuticals extracted from raw birds’ nest and seaweed
  • Focus on sales and distribution in China
Nutura is a Melbourne-based company which produces a range of nutrition products made exclusively from Australian sourced milk including its GB-compliant product "Adult 60+ Milk Formula" (Adult Milk Formula). Nutura is interested in expanding its product and distribution footprint throughout China. “GB compliant” is a reference to a product which has passed the product testing protocols and procedures prescribed by the National Standards of the People’s Republic of China.

As part of it continuing focus on opportunities to purchase or produce food products which deliver Traditional Chinese Medicine (TCM)-based outcomes, the Company is keen to undertake a pilot program in China to test the market for the sale and distribution of Nutura’s Adult Milk Formula and the opportunities to infuse that formula with TCM-based ingredients including sialic acid and nutraceuticals extracted from raw birds’ nest and seaweed (Pilot Study).

By committing to purchase an initial quantity of the Adult Milk Formula, the Company can commence a pilot study in China to determine the feasibility and commerciality of selling the Adult Milk Formula infused with TCM-based ingredients in China, including:

  • The cost of shipping the Adult Milk Formula to China and clearing Chinese customs procedures and protocols;
  • The cost of obtaining the TCM-based ingredients, either in Australia or China, and infusing those ingredients into the Adult Milk Formula;
  • The cost of delivery of the Adult Milk Formula to retail outlets; and
  • The level of consumer demand.

Term Sheet

Key terms of the Term Sheet are as follows:

  • Product: Adult Milk Formula.
  • Quantity and Price: 3,500 units at an aggregate purchase price of approximately AUD35,000, after a rebate provide by Nutura to support marketing and promotional activities associated with the Pilot Study (Purchase Order)
  • Nutura to ensure that the Adult Milk Formula is GB compliant.
  • The term of the Term Sheet is valid until completion of each of the Company’s and Nutura’s obligations regarding the Purchase Order
  • Future Activities: Nutura and the Company will continue to discuss commercial opportunities for the supply of Nutura’s products in the Chinese markets for their mutual commercial benefit with a focus on the Adult Milk Formula infused with TCM-based ingredients and leveraging the Company’s sales and distribution network in China.

This article includes content from BPH Global Ltd, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BP8:AU
BPH Global

BPH Global Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BPH Global

BPH Global

Stemcell United Ltd is a marine and agricultural biotechnology industry. Its only operating segment being sourcing, producing, marketing, and selling traditional medicines. The company's geographical segment includes Australia; Singapore; Malaysia and Greater China. The company's product includes Cannabis sativa; Dendrobium Officinale and Daemonorops Draco Blume.

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024

Data From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell Engagers

Overall Survival Data from Phase 3 LUMAKRAS ® (sotorasib) Plus Vectibix ® (panitumumab) in Metastatic Colorectal Cancer Accepted as Late-Breaking Oral Presentation

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD

Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels

Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire ® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significant (90% CI: -6, 36; p[1-sided]=0.1042). The results will be featured in presentations at the American Thoracic Society (ATS) International Conference, May 17-22 in San Diego .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

FDA APPROVES IMDELLTRA , THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor

IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024

Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday May 20, 2024 following the presentation of new data from TEZSPIRE ® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, and other members of the Amgen team will participate. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Sirona Biochem Engages Stonegate Healthcare Partners

Sirona Biochem Engages Stonegate Healthcare Partners

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services. Leveraging Stonegate's extensive global network of corporate and institutional investor relationships, Stonegate has begun an evaluation of Sirona's anti-aging ingredient, GlycoProteMimTM, to effectively assess and demonstrate its market potential within the global anti-aging skincare industry.

About Sirona Biochem Corp.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BPH Global

BPH Global Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×